Latest Articles

Severe acute respiratory syndrome coronavirus-2, the causal agent of the ongoing coronavirus pandemic, has been evolving ever since the first outbreak in December 2019. Researchers believe that rapid vaccination is the most effective strategy to contain the pandemic.

Oral vaccines are less immunogenic when administered in low-income countries compared to high-income countries. Several factors can contribute to this reduced efficacy, including enteric dysfunction. Technology Networks spoke with Dr. Timothy Hand, to learn about his research in this area.

This article explores how immunopeptidomics can be used to accurately determine HLA-II peptide-binding motifs and its recent utilization in exploring peptide presentation in response to SARS-CoV-2, demonstrating the capability of this technique to reveal additional insights to support therapeutic development.

A shift toward automation is a vital step forward to making breakthrough therapies more scalable and viable to help save patients’ lives. While the hurdles must be carefully considered, it is now time to accelerate digital transformation to enable the application of smart technologies, and specifically, to advance the cell and gene therapy industry.

Technology Networks is committed to keeping you updated with the latest research in this space. Here, you'll find a curation of our latest COVID-19 vaccine-related content.

This article will discuss how synthetic biology principles can be applied at various stages of therapeutic development – from elucidating disease mechanisms and identifying drug targets to producing therapeutics at scale.

In this honest account, science writer Leo Bear-McGuinness shares what it's like to live with long COVID as a "long-hauler", and explores how the condition has awakened an urgency in post-viral research.

What research has been conducted that explores menstrual cycles throughout the COVID-19 global pandemic? How scientifically sound are these studies, and what can they tell us? In this interview, we spoke with Dr. Gemma Sharp and Dr. Kayleigh Easey to learn about research gaps and opportunities in this space.

Technology Networks spoke to Hiroshi Kiyono, DDS, PhD, from the Institute of Medical Science at the University of Tokyo who is currently also affiliated with Chiba University and University of California, San Diego, to find out more about MucoRice-CTB, a room-temperature stable oral vaccine being developed using genetically modified rice plants.

Dr. Yi Shi, assistant professor in the department of cell biology at the University of Pittsburgh and colleagues are exploring the potential of nanobodies as a treatment for COVID-19. The team recently published findings from preclinical studies on the use of a nanobody called Pittsburgh inhalable Nanobody-21 (PiN-21) that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein.